CryoLife announced today that it has completed its previously announced acquisition of JOTEC.
| |
| [01-December-2017] |
| ATLANTA, Dec. 1, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of JOTEC AG, a German-based, privately-held developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts, focused on aortic repair. About CryoLife Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable living tissues used in cardiac and vascular surgical procedures. CryoLife markets and sells a highly competitive product portfolio focused on treating aortic disease in more than 80 countries worldwide. For additional information about CryoLife, visit our website, www.cryolife.com. Contacts: CryoLife The Ruth Group D. Ashley Lee Zack Kubow Executive Vice President, Chief Financial Officer and 646-536-7020 Chief Operating Officer Phone: 770-419-3355 zkubow@theruthgroup.com
View original content with multimedia:http://www.prnewswire.com/news-releases/cryolife-completes-acquisition-of-jotec-300565402.html SOURCE CryoLife, Inc. | ||
Company Codes: NYSE:CRY |
